A Phase 2 interventional study of Ondansetron and Normal saline in Cholecystitis, sponsored by National Hepatology & Tropical Medicine Research Institute. Completed at 1 site in Egypt. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-01-12.
Sponsored by National Hepatology & Tropical Medicine Research Institute · Phase 2, Interventional, and Treatment
Laparoscopic cholecystectomy (LC) is an easy procedure characterized by its minimal invasiveness, less post-operative pain and early recovery when compared to the open conventional cholecystectomy. However, patients who have undergone LC still complain of postoperative pain. It has been reported that ondansetron produces numbness when injected under the skin and has local anesthetic effect that is 15 times more potent than lidocaine the most widely used local anesthetic and probably explains its antiemetic action. It possesses anti-inflammatory, anesthetic, and analgesic properties by its multifaceted actions as a 5-HT3 receptor antagonist, a Na channel blocker, and a mu-opioid agonist which may have a potential role in decreasing pain. The study aimed to demonstrate the effectiveness of IP administration of ondansetron on pain management post LC.
266 studies on the registry are indexed under Cholecystitis; 46 are open to participants now.
This study's enrollment of 50 is below the median of 86 across 167 interventional studies indexed under Cholecystitis.
Browse Cholecystitis studies →National Hepatology & Tropical Medicine Research Institute is the lead sponsor of 19 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Ondansetron intraperitoneal in the gall bladder bed
Drug: Ondansetron
Normal saline intraperitoneal in the gall bladder bed
Drug: Normal saline
Interperitoneal administration in the gall bladder bed
Interperitoneal administration in the gall bladder bed
change in postoperative pain between the two groups using visual analogue score (VAS)
Time frame: 24 hours
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Hepatology & Tropical Medicine Research Institute